Mycoplasma Testing Market is valued at USD 861.90 million in 2022 and is projected to reach a value of USD 2323.97 million in 2030 expanding at a CAGR of 13.2% over the forecast period of 2022-2030.
Testing for mycoplasma is done to look for contamination in biological samples. It is anticipated that rising R&D expenses and the introduction of new products will fuel the expansion of the mycoplasma testing market. The market for mycoplasma testing will, however, be constrained in its expansion over the projected period by the availability of substitute conventional procedures. Product, technique, and application categories make up the mycoplasma testing market. The kits and reagents segment, the instruments segment, and the services segment make up the market. The kits and reagents category is anticipated to hold the largest share of the market in 2017.
The main source of contamination in the manufacture of biopharmaceuticals, tissue engineering, and stem cells is mycoplasma. These mycoplasma tests are carried out by biotech and pharmaceutical businesses to comprehend and analyse the morphological changes, changed growth rates, metabolism, and chromosomal mutations. It is also used to test finished and bulk pharmaceutical items. Growing government assistance for biotech and pharmaceutical businesses to employ mycoplasma testing, together with an increase in cell culture contamination, are the main factors that are responsible for the market’s expansion. Rising research and development activities in the life sciences sector.
The Mycoplasma Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Mycoplasma Testing Market- Segmentation
The Mycoplasma Testing Market is sub-segmented into product, technology, application, and end-use.
Based on Product
• Instruments
• Kits & Reagents
o PCR Assays
o Nucleic Acid Detection Kits
o Stains
o Elimination Kits
o Standards & Controls
o Others
• Services
Based on Technology
• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods
Based on Application
• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others
Based on End-use
• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others
Mycoplasma Testing Market- Regional Segmentation
The Mycoplasma Testing Market is segmented into 4 main regions namely, North America, Europe, Asia Pacific, and Middle east and Africa. Among these, North America has dominated the market growth over the forecast period. This is because of its established healthcare sector and the increased incidence of respiratory disorders. Also, the existence of multinational pharmaceutical and biotech companies as well as increased investment in R&D activities have boosted the market growth in the region.
Mycoplasma Testing Market- Key Market Players
Some of the prominent companies operating in the market are Thermo Fisher Scientific, Inc.; Merck KGaA; Lonza Group AG; Charles River Laboratories International, Inc.; PromoCell GmbH; American Type Culture Collection; Asahi Kasei Medical Co. Ltd.; Sartorius AG; InvivoGen; Eurofins Scientific.
COVID-19 Impact
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Mycoplasma Testing Kits & Reagents market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Frequently Asked Questions About This Report
- How big is this market?
- What is this market growth?
- Which segment accounted for this market share?
- Who are the key players in this market?
- What are the factors driving this market?
